Home » Topics » Regulatory » Patents

Patents
RSS

Cor Therapeutics patents novel factor Xa inhibitors

July 9, 1998

Immunosuppressive potassium channel blockers from Merck & Co.

July 9, 1998

Adenosine derivatives useful for CNS and cardiovascular disorders

July 9, 1998

Caspase inhibitors in development at Warner-Lambert

July 9, 1998

Broad-spectrum antiviral compounds prepared at Astra

July 8, 1998

GH secretatogues from Fujisawa

July 8, 1998

New immunosuppressants from Merck & Co. acting on potassium channels

July 8, 1998

Inhibitors of protein kinase GSK3 prepared at Chiron, U. of California

July 8, 1998

Cor Therapeutics describes selective factor Xa inhibitors

July 8, 1998

PDE V inhibitors for heart failure, impotence claimed by Merck KGaA

July 8, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.